

DÃ©sirÃ©e E Larenas-Linnemann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5130675/publications.pdf>

Version: 2024-02-01

143
papers

15,020
citations

41344

49
h-index

18647

119
g-index

168
all docs

168
docs citations

168
times ranked

9644
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus on mild asthma management: results of a modified Delphi study. <i>Journal of Asthma</i> , 2023, 60, 145-157.	1.7	7
2	Beyond eosinophilia: inflammatory patterns in patients with asthma. <i>Journal of Asthma</i> , 2022, 59, 255-263.	1.7	8
3	The international EAACI/GAÅ²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	5.7	392
4	Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 63-78.	3.4	41
5	Development and validation of combined symptom&€ medication scores for allergic rhinitis*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2147-2162.	5.7	32
6	An independent in&€ depth analysis proposing adjusted Global Initiative on Asthma Step 1&€2 treatment suggestions. <i>Clinical and Experimental Allergy</i> , 2022, 52, 493-511.	2.9	3
7	Allergen immunotherapy in MASK&€air users in real&€life: Results of a Bayesian mixed&€effects model. <i>Clinical and Translational Allergy</i> , 2022, 12, e12128.	3.2	9
8	Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK&€air^{Å®} real&€world data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2699-2711.	5.7	17
9	Comparison of rhinitis treatments using <scp>MASK</scp>&€air&€ data and considering the minimal important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3002-3014.	5.7	8
10	House dust mite liquid SLIT effective in atopic dermatitis even with suboptimal dosing. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1936-1937.	3.8	1
11	Long-term adherence strategies for allergen immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 299-304.	2.2	6
12	Anxiety and depression in adult patients with asthma: the role of asthma control, obesity and allergic sensitization. <i>Journal of Asthma</i> , 2021, 58, 1058-1066.	1.7	11
13	COVID&€19 pandemic: Practical considerations on the organization of an allergy clinic&€”An EAACI/ARIA Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 648-676.	5.7	79
14	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
15	ARIA&€EAACI statement on asthma and COVID&€19 (June 2, 2020). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 689-697.	5.7	57
16	Thirty&€six COVID&€19 cases preventively vaccinated with mumps&€measles&€rubella vaccine: All mild course. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 910-914.	5.7	20
17	CME suggestions for pediatricians, allergists, and dermatologists, directed by an online survey on urticaria knowledge. <i>Allergologia Et Immunopathologia</i> , 2021, 49, 87-94.	1.7	0
18	Cutaneous Manifestations Related to COVID-19 Immune Dysregulation in the Pediatric Age Group. <i>Current Allergy and Asthma Reports</i> , 2021, 21, 13.	5.3	15

#	ARTICLE	IF	CITATIONS
19	Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EEAACI-EGA ² LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
20	The Role of Mobile Health Technologies in Stratifying Patients for AIT and Its Cessation: The ARIA-EEAACI Perspective. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 1805-1812.	3.8	14
21	Coronavirus disease 2019, allergic diseases, and allergen immunotherapy: Possible favorable mechanisms of interaction. Allergy and Asthma Proceedings, 2021, 42, 187-197.	2.2	13
22	Comparing Antihistamines in Chronic Spontaneous Urticaria: Possible Future Directions. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 2272-2273.	3.8	0
23	Intranasal Corticosteroids: Topical Potency, Systemic Activity and Therapeutic Index. Journal of Asthma and Allergy, 2021, Volume 14, 1093-1104.	3.4	9
24	Impact of Socioeconomic Status on Adult Patients with Asthma: A Population-Based Cohort Study from UK Primary Care. Journal of Asthma and Allergy, 2021, Volume 14, 1375-1388.	3.4	13
25	Leukotriene Receptor Antagonists and the Risk of Neuropsychiatric Disease: Could There Be a Genetic Predisposition?. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 4298-4299.	3.8	3
26	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272
27	Risk factors for wheezing in primary health care settings in the tropics. Annals of Allergy, Asthma and Immunology, 2020, 124, 179-184.e1.	1.0	8
28	Author response. Annals of Allergy, Asthma and Immunology, 2020, 125, 116.	1.0	0
29	Gaps in allergen immunotherapy administration and subcutaneous allergen immunotherapy dose adjustment schedules. Annals of Allergy, Asthma and Immunology, 2020, 125, 505-506.e2.	1.0	12
30	Compromising between European and US allergen immunotherapy schools: Discussions from GUIMIT, the Mexican immunotherapy guidelines. World Allergy Organization Journal, 2020, 13, 100444.	3.5	5
31	Coronavirus disease 2019 and allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2020, 125, 247-249.	1.0	10
32	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. Clinical and Translational Allergy, 2020, 10, 16.	3.2	97
33	Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EEAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2440-2444.	5.7	114
34	Acute emotional stress proposed as a risk factor for anaphylaxis in patients receiving allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2020, 124, 314-317.	1.0	4
35	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air [®] App. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1672-1688.	5.7	32
36	Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EEAACI statement. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1546-1554.	5.7	87

#	ARTICLE	IF	CITATIONS
37	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 321-333.	2.1	108
38	Food allergen sensitization patterns in a large allergic population in Mexico. <i>Allergologia Et Immunopathologia</i> , 2020, 48, 553-559.	1.7	13
39	Prevalence and triggers of self-reported nasal hyperreactivity in adults with asthma. <i>World Allergy Organization Journal</i> , 2020, 13, 100132.	3.5	9
40	Enhancing innate immunity against virus in times of COVID-19: Trying to untangle facts from fictions. <i>World Allergy Organization Journal</i> , 2020, 13, 100476.	3.5	33
41	<p>Perceptions and Management of Allergic Rhinitis Among Ecuadorian Otorhinolaryngologists: A Survey-Based Study</p>. <i>Journal of Multidisciplinary Healthcare</i> , 2020, Volume 13, 1975-1981.	2.7	1
42	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergo Journal International</i> , 2019, 28, 255-276.	2.0	22
43	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
44	Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 135-143.e6.	2.9	101
45	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. <i>Clinical and Translational Allergy</i> , 2019, 9, 16.	3.2	81
46	2019 ARIA Care pathways for allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2087-2102.	5.7	140
47	Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2511-2523.	3.8	44
48	<sc>ARIA</sc> pharmacy 2018 âœAllergic rhinitis care pathways for community pharmacyâœ. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
49	Adherence to treatment in allergic rhinitis using mobile technology. The <sc>MASK</sc> Study. <i>Clinical and Experimental Allergy</i> , 2019, 49, 442-460.	2.9	73
50	The characterization of asthma with blood eosinophilia in adults in Latin America. <i>Journal of Asthma</i> , 2019, 56, 1138-1146.	1.7	6
51	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
52	ARIA guideline 2019: treatment of allergic rhinitis in the German health system. <i>Allergologie Select</i> , 2019, 3, 22-50.	3.1	70
53	Chronic urticaria can be caused by cancer and resolves with its cure. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1562-1566.	5.7	16
54	Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <sc>MASK</sc> study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1622-1631.	5.7	69

#	ARTICLE	IF	CITATIONS
55	What you should not miss from the systematic reviews and meta-analyses on allergen-specific immunotherapy in 2017. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 168-176.	2.3	11
56	The EAACI/GAÄ²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1393-1414.	5.7	1,008
57	Treatment of allergic rhinitis using mobile technology with realâ€world data: The <scp>MASK</scp> observational pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1763-1774.	5.7	94
58	International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. <i>International Forum of Allergy and Rhinology</i> , 2018, 8, 108-352.	2.8	273
59	Pediatric asthma treatment. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 7-13.e4.	1.0	4
60	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<scp>MACVIA</scp>â€<scp>ARIA</scp>) â€•<scp>EIP</scp> on <scp>AHA</scp> Twinning Reference Site (<scp>GARD</scp> research demonstration project). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 77-92.	5.7	54
61	National clinical practice guidelines for allergen immunotherapy: An international assessment applying <scp>AGREE</scp>â€<scp>II</scp>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 664-672.	5.7	35
62	EAACI Guidelines on Allergen Immunotherapy: Allergic rhinoconjunctivitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 765-798.	5.7	473
63	The Allergic Rhinitis and its Impact on Asthma (ARIA) score of allergic rhinitis using mobile technology correlates with quality of life: The MASK study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 505-510.	5.7	77
64	Moving toward consensus on diagnosis and management of severe asthma in children. <i>Current Medical Research and Opinion</i> , 2018, 34, 447-458.	1.9	7
65	â¼²é™...è¼•æ•šžé¼»çš‘â¼•â¼•±è¼•â¼•æž : â¼•â¼•æššé¼»çž. <i>International Forum of Allergy and Rhinology</i> , 2018, 8, 108-352		24
66	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	3.2	104
67	Very rarely chronic urticaria can be caused by cancer and if so, resolves with its cure. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1925-1926.	5.7	5
68	The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 42-44.	1.3	37
69	Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study. <i>World Allergy Organization Journal</i> , 2018, 11, 15.	3.5	33
70	Electronic Clinical Decision Support System for allergic rhinitis management: MASK eâ€CDSS. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1640-1653.	2.9	61
71	Pollen in the atmosphere of Mexico City and its impact on the health of the pediatric population. <i>Atmospheric Environment</i> , 2018, 186, 198-208.	4.1	20
72	Update on Omalizumab for Urticaria: Whatâ€™s New in the Literature from Mechanisms to Clinic. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 33.	5.3	27

#	ARTICLE	IF	CITATIONS
73	Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future – an EAACI Position Paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1035-1042.	5.7	85
74	Work productivity in rhinitis using cell phones: The MASK pilot study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1475-1484.	5.7	69
75	Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1597-1631.	5.7	233
76	Physicians' experience and opinion on contraindications to allergen immunotherapy: The CONSIT survey. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 621-628.e1.	1.0	13
77	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 950-958.	2.9	1,199
78	Allergen immunotherapy is safe during pollen season. Results of a 10-year, real-life prospective study. <i>Revue Francaise D'allergologie</i> , 2017, 57, 302-307.	0.2	0
79	American Academy of Asthma, Allergy & Immunology membership experience with venom immunotherapy in chronic medical conditions and pregnancy, and in young children. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 121-129.	2.2	13
80	EAACI guidelines on allergen immunotherapy: Prevention of allergy. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 728-745.	2.6	171
81	Treatment of seasonal allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 489-511.e41.	1.0	133
82	Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis. <i>Pediatric Allergy and Immunology</i> , 2017, 28, 18-29.	2.6	155
83	Worldwide allergen immunotherapy guidelines: Evidence and experience-based. <i>Allergologia Et Immunopathologia</i> , 2017, 45, 17-22.	1.7	1
84	CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel Network) Good Practice in allergic rhinitis: a SUNFRIL report. <i>Clinical and Translational Allergy</i> , 2017, 7, 37.	3.2	36
85	Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. <i>Clinical and Translational Allergy</i> , 2017, 7, 24.	3.2	49
86	Debates in Allergy Medicine: Allergy skin testing cannot be replaced by molecular diagnosis in the near future. <i>World Allergy Organization Journal</i> , 2017, 10, 32.	3.5	27
87	How does the efficacy and safety of Oralair compare to other products on the market?. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 831.	2.0	18
88	Allergen immunotherapy for the prevention of allergic disease: protocol for a systematic review. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 236-241.	2.6	13
89	American Academy of Allergy, Asthma & Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions. <i>Allergy and Asthma Proceedings</i> , 2016, 37, 112-122.	2.2	15
90	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	3.2	121

#	ARTICLE	IF	CITATIONS
91	Procedures to Assist Health Care Providers to Determine When Home Assessments for Potential Mold Exposure Are Warranted. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 417-422.e2.	3.8	29
92	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	2.9	128
93	Direct comparison of efficacy of sublingual immunotherapy tablets for rhinoconjunctivitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 274-286.	1.0	8
94	Home Assessment and Remediation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 423-431.e15.	3.8	25
95	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	3.2	47
96	Similar biological activity in skin prick test for Oralair [®] (8200 <scp>BAU</scp>) and Grazax [®] (6200 <scp>BAU</scp>) reinforces effective SLIT dosing level. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1782-1786.	5.7	7
97	Dosing of European sublingual immunotherapy maintenance solutions relative to monthly recommended dosing of subcutaneous immunotherapy. <i>Allergy and Asthma Proceedings</i> , 2016, 37, 50-56.	2.2	26
98	Allergen immunotherapy for allergic rhinoconjunctivitis: protocol for a systematic review. <i>Clinical and Translational Allergy</i> , 2016, 6, 12.	3.2	14
99	Clinical Evaluation and Management of Patients with Suspected Fungus Sensitivity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 405-414.	3.8	37
100	Exposure and Health Effects of Fungi on Humans. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 396-404.	3.8	157
101	Innate and Adaptive Immune Response to Fungal Products and Allergens. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 386-395.	3.8	43
102	Taxonomy of Allergenic Fungi. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 375-385.e1.	3.8	80
103	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
104	Allergen immunotherapy on the way to product-based evaluationâ€”a WAO statement. <i>World Allergy Organization Journal</i> , 2015, 8, 29.	3.5	70
105	Allergen immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 556-567.	2.3	9
106	Patient selection for subcutaneous versus sublingual immunotherapy. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 588-595.	2.3	4
107	Allergic Sensitization and Rhinitis in Children: What Is New?. <i>Current Treatment Options in Allergy</i> , 2015, 2, 20-31.	2.2	0
108	Patient-reported outcomes and quality-of-life questionnaires in the assessment of rhinoconjunctivitis in childhood. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2014, 14, 192-199.	2.3	8

#	ARTICLE	IF	CITATIONS
109	Use of omalizumab to improve desensitization safety inÄallergen immunotherapy. Journal of Allergy and Clinical Immunology, 2014, 133, 937-937.e2.	2.9	33
110	Allergen sensitization linked to climate and age, not to intermittentÄpersistent rhinitis in a crossÄsectional cohort study in the (sub)tropics. Clinical and Translational Allergy, 2014, 4, 20.	3.2	43
111	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal, 2014, 7, 6.	3.5	395
112	In the (Sub)Tropics Allergic Rhinitis and Its Impact on Asthma Classification of Allergic Rhinitis is More Useful than PerennialÄSeasonal Classification. American Journal of Rhinology and Allergy, 2014, 28, 232-238.	2.0	10
113	Environmental assessment and exposure control of dust mites: a practice parameter. Annals of Allergy, Asthma and Immunology, 2013, 111, 465-507.	1.0	128
114	Author response. Annals of Allergy, Asthma and Immunology, 2013, 111, 306-307.	1.0	1
115	Grading local side effects of sublingual immunotherapy forÄrespiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	2.9	144
116	Will Sublingual Immunotherapy Offer Benefit for Asthma?. Current Allergy and Asthma Reports, 2013, 13, 571-579.	5.3	5
117	Allergy training and immunotherapy in Latin America: results of a regional overview. Annals of Allergy, Asthma and Immunology, 2013, 111, 415-419.e1.	1.0	20
118	Pediatric sublingual immunotherapy efficacy: evidence analysis, 2009-2012. Annals of Allergy, Asthma and Immunology, 2013, 110, 402-415.e9.	1.0	43
119	Over Diagnosis of Persistent Allergic Rhinitis in Perennial Allergic Rhinitis Patients: A Nationwide Study in Mexico. American Journal of Rhinology and Allergy, 2013, 27, 495-501.	2.0	12
120	Adjuvants for immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 648-657.	2.3	52
121	One hundred years of immunotherapy: Review of the first landmark studies. Allergy and Asthma Proceedings, 2012, 33, 122-128.	2.2	20
122	Food and Drug Administration reclassification of allergens for diagnosis and treatment: now is the time to be heard. Annals of Allergy, Asthma and Immunology, 2012, 109, 6-9.	1.0	4
123	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. Journal of Allergy and Clinical Immunology, 2012, 130, 1049-1062.	2.9	486
124	Survey on immunotherapy practice patterns: dose, dose adjustments, and duration. Annals of Allergy, Asthma and Immunology, 2012, 108, 373-378.e3.	1.0	22
125	European and Mexican vs US diagnostic extracts of Bermuda grass and cat in skin testing. Annals of Allergy, Asthma and Immunology, 2011, 106, 421-428.	1.0	16
126	Maintenance dosing for sublingual immunotherapy by prominent European allergen manufacturers expressed in bioequivalent allergy units. Annals of Allergy, Asthma and Immunology, 2011, 107, 448-458.e3.	1.0	43

#	ARTICLE	IF	CITATIONS
127	Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward. <i>Annals of Allergy, Asthma and Immunology</i> , 2011, 107, 407-416.e11.	1.0	25
128	Patterns of skin prick test positivity in allergic patients: usefulness of a nationwide SPT chart review. <i>Allergologia Et Immunopathologia</i> , 2011, 39, 330-336.	1.7	15
129	Development and implementation of guidelines in allergic rhinitis â€“ an ARIAâ€™GA²LEN paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1212-1221.	5.7	85
130	Skin prick test evaluation of <i>Dermatophagoides pteronyssinus</i> diagnostic extracts from Europe, Mexico, and the United States. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 104, 420-425.	1.0	16
131	Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 569-574.e7.	2.9	406
132	A comparison of in vitro potency between European and Mexican allergen extracts and US (CBER/FDA) reference extracts. <i>Allergologia Et Immunopathologia</i> , 2010, 38, 170-173.	1.7	16
133	Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. <i>Current Opinion in Investigational Drugs</i> , 2010, 11, 586-96.	2.3	10
134	Sublingual immunotherapy in children: complete and updated review supporting evidence of effect. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 168-176.	2.3	42
135	Subâ€™lingual Immunotherapy: World Allergy Organization Position Paper 2009. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1-59.	5.7	316
136	Sublingual immunotherapy in children: more optimism today. <i>Pediatric Allergy and Immunology</i> , 2009, 20, 399-400.	2.6	5
137	Briefings from ACAAI 2008 Annual meeting. <i>Therapy: Open Access in Clinical Medicine</i> , 2009, 6, 279-283.	0.2	1
138	Certainties and doubts about sublingual and oral immunotherapy in children. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 558-567.	2.3	15
139	Subcutaneous and sublingual immunotherapy in children: Complete update on controversies, dosing, and efficacy. <i>Current Allergy and Asthma Reports</i> , 2008, 8, 465-474.	5.3	17
140	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 8-160.	5.7	3,827
141	European allergen extract units and potency: review of available information. <i>Annals of Allergy, Asthma and Immunology</i> , 2008, 100, 137-145.	1.0	93
142	Sublingual immunotherapy: Dosing in relation to clinical and immunological efficacy. <i>Allergy and Asthma Proceedings</i> , 2008, 29, 130-139.	2.2	11
143	Sublingual immunotherapy: A comprehensive review. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1021-1035.	2.9	371